Literature DB >> 29522281

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

Matthew Tamplen1, Tristan Fowler2, Jeffery Markey1, P Daniel Knott1, Larry J Suva3, Tamara Alliston1,2.   

Abstract

BACKGROUND: Anti-Sclerostin antibody (Scl-Ab) is a promising new bone anabolic therapy. Although anti-Scl-Ab stimulates bone formation and repair in the appendicular and axial skeleton, its efficacy in the craniofacial skeleton is still poorly understood.
METHODS: Using an established model of Down syndrome-dependent bone deficiency, 10 Ts65Dn mice and 10 wild-type mice were treated weekly via i.v. tail vein injection with vehicle or anti-Sclerostin for 3 weeks and euthanized 1 week after.
RESULTS: Wild-type mice treated with the anti-Scl-Ab had increased mandibular bone, trabecular thickness, and alveolar height compared with controls. Anti-Scl-Ab increased Ts65Dn mandibular bone parameters such that they were statistically indistinguishable from those in vehicle-treated wild-type mandibles.
CONCLUSION: Treatment with anti-Scl-Ab significantly increased mandibular bone mass and alveolar height in wild type mice and normalized mandibular bone mass and alveolar height in Ts65Dn mice. The anti-Scl-Ab therapy represents a novel method for increasing mandibular bone formation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  head and neck reconstruction; mandible; micro-CT; osteoradionecrosis; sclerostin

Mesh:

Substances:

Year:  2018        PMID: 29522281      PMCID: PMC6037571          DOI: 10.1002/hed.25128

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  39 in total

Review 1.  Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

Authors:  Hua Zhu Ke; William G Richards; Xiaodong Li; Michael S Ominsky
Journal:  Endocr Rev       Date:  2012-06-20       Impact factor: 19.871

2.  Increased risk of tooth loss is related to bone loss at the whole body, hip, and spine.

Authors:  E A Krall; R I Garcia; B Dawson-Hughes
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

3.  Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair.

Authors:  Chan Ho Park; Zachary R Abramson; Mario Taba; Qiming Jin; Jia Chang; Jaclynn M Kreider; Steven A Goldstein; William V Giannobile
Journal:  J Periodontol       Date:  2007-02       Impact factor: 6.993

4.  Genetic analysis of Down syndrome-associated heart defects in mice.

Authors:  Chunhong Liu; Masae Morishima; Tao Yu; Sei-Ichi Matsui; Li Zhang; Dawei Fu; Annie Pao; Alberto C Costa; Katheleen J Gardiner; John K Cowell; Norma J Nowak; Normal J Nowak; Michael S Parmacek; Ping Liang; Antonio Baldini; Y Eugene Yu
Journal:  Hum Genet       Date:  2011-03-26       Impact factor: 4.132

5.  Osteoradionecrosis of the mandible: pathogenesis.

Authors:  J Bras; H K de Jonge; J P van Merkesteyn
Journal:  Am J Otolaryngol       Date:  1990 Jul-Aug       Impact factor: 1.808

6.  Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.

Authors:  Michael S Ominsky; Chaoyang Li; Xiaodong Li; Hong L Tan; Edward Lee; Mauricio Barrero; Franklin J Asuncion; Denise Dwyer; Chun-Ya Han; Fay Vlasseros; Rana Samadfam; Jacquelin Jolette; Susan Y Smith; Marina Stolina; David L Lacey; William S Simonet; Chris Paszty; Gang Li; Hua Z Ke
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

7.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

8.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

9.  Low bone turnover and low bone density in a cohort of adults with Down syndrome.

Authors:  K D McKelvey; T W Fowler; N S Akel; J A Kelsay; D Gaddy; G R Wenger; L J Suva
Journal:  Osteoporos Int       Date:  2012-08-18       Impact factor: 4.507

10.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

View more
  3 in total

1.  A 3D, Dynamically Loaded Hydrogel Model of the Osteochondral Unit to Study Osteocyte Mechanobiology.

Authors:  Rachel L Wilmoth; Virginia L Ferguson; Stephanie J Bryant
Journal:  Adv Healthc Mater       Date:  2020-10-19       Impact factor: 9.933

2.  Low bone mass and impaired fracture healing in mouse models of Trisomy21 (Down syndrome).

Authors:  Kirby M Sherman; Diarra K Williams; Casey A Welsh; Alexis M Cooper; Alyssa Falck; Shannon Huggins; Rihana S Bokhari; Dana Gaddy; Kent D McKelvey; Lindsay A Dawson; Larry J Suva
Journal:  Bone       Date:  2022-06-15       Impact factor: 4.626

3.  Activation of Wnt signalling reduces the population of cancer stem cells in ameloblastoma.

Authors:  Hyun-Yi Kim; Shujin Li; Dong-Joon Lee; Jin Hoo Park; Takashi Muramatsu; Hidemitsu Harada; Young-Soo Jung; Han-Sung Jung
Journal:  Cell Prolif       Date:  2021-06-06       Impact factor: 6.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.